Boston Scientific Corporation (BSX) Receives $30.91 Consensus Price Target from Analysts

Boston Scientific Corporation (NYSE:BSX) has been assigned a consensus rating of “Buy” from the twenty-one research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $30.91.

BSX has been the topic of several analyst reports. BMO Capital Markets increased their target price on Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. SunTrust Banks set a $33.00 target price on Boston Scientific and gave the company a “buy” rating in a research note on Monday, December 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a research report on Tuesday, January 16th. Evercore ISI began coverage on Boston Scientific in a research report on Wednesday, January 3rd. They set an “in-line” rating and a $27.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $31.00 price target on shares of Boston Scientific in a research report on Tuesday, November 7th.

Boston Scientific (NYSE BSX) traded up $0.10 during trading hours on Tuesday, reaching $27.20. The company’s stock had a trading volume of 6,710,000 shares, compared to its average volume of 9,700,000. Boston Scientific has a 1 year low of $23.29 and a 1 year high of $29.93. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $37,350.00, a price-to-earnings ratio of 38.86, a price-to-earnings-growth ratio of 1.97 and a beta of 0.81.

Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, meeting the consensus estimate of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The firm had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. During the same quarter in the prior year, the firm posted $0.30 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. sell-side analysts expect that Boston Scientific will post 1.37 EPS for the current year.

In related news, SVP Maulik Nanavaty sold 15,568 shares of Boston Scientific stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $25.38, for a total value of $395,115.84. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The stock was purchased at an average cost of $0.45 per share, for a total transaction of $183,602.70. In the last three months, insiders sold 177,032 shares of company stock worth $4,648,733. 0.74% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Truewealth LLC acquired a new stake in Boston Scientific in the 4th quarter valued at approximately $116,000. Icon Wealth Partners LLC bought a new position in Boston Scientific in the fourth quarter valued at approximately $117,000. Valeo Financial Advisors LLC bought a new position in Boston Scientific in the third quarter valued at approximately $138,000. Steward Partners Investment Advisory LLC bought a new position in Boston Scientific in the third quarter valued at approximately $139,000. Finally, Cerebellum GP LLC bought a new position in Boston Scientific in the fourth quarter valued at approximately $126,000. 89.84% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Boston Scientific Corporation (BSX) Receives $30.91 Consensus Price Target from Analysts” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/18/boston-scientific-corporation-bsx-receives-30-91-consensus-price-target-from-analysts.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply